# A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

> **NCT01539512** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 220 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Idelalisib
- **DRUG:** Rituximab
- **DRUG:** Placebo to match idelalisib

## Key facts

- **NCT ID:** NCT01539512
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2013-10
- **Final completion:** 2014-04
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2019-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01539512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01539512, "A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01539512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*